Candel Therapeutics (CADL) Expected to Announce Quarterly Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Candel Therapeutics to post earnings of ($0.23) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.17). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Stock Performance

Shares of CADL stock opened at $8.66 on Tuesday. Candel Therapeutics has a 52 week low of $1.45 and a 52 week high of $14.60. The company has a market capitalization of $281.24 million, a price-to-earnings ratio of -5.01 and a beta of -1.29. The company has a 50-day simple moving average of $8.24 and a 200 day simple moving average of $7.04.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CADL. Canaccord Genuity Group upped their target price on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Citigroup began coverage on Candel Therapeutics in a report on Thursday, February 20th. They issued a “buy” rating and a $25.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $19.00 target price on shares of Candel Therapeutics in a report on Friday, March 14th. Finally, Bank of America started coverage on shares of Candel Therapeutics in a research report on Friday, February 7th. They issued a “buy” rating and a $15.00 target price for the company.

Insider Activity at Candel Therapeutics

In other news, insider Charles Schoch sold 5,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.83, for a total transaction of $44,150.00. Following the completion of the sale, the insider now directly owns 38,038 shares in the company, valued at approximately $335,875.54. This represents a 11.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Francesca Barone sold 13,534 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $7.22, for a total value of $97,715.48. Following the sale, the insider now directly owns 110,673 shares in the company, valued at approximately $799,059.06. This trade represents a 10.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 77,807 shares of company stock worth $633,534. Company insiders own 41.60% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.